Comprehending the dynamics behind how Glp 1 Agonist work provides clarity regarding their important role not only with respect to diabetes care, but also concerning obesity therapy
The expression of GLP-1 and/or GLP-1R was found in hypothalamic feeding centers (28, 29), hindbrain matrix (30), the lateral parabrachial nucleus of the posterior nucleus (31), and mesolimbic substrates (3234), etc
GIP also modulates adipocyte lipid handling, improving postprandial lipid clearance
For example: Semaglutide for diabetes (Ozempic): Start at 0.25 mg weekly for 4 weeks, increase to 0.5 mg, then potentially to 1 mg or 2 mg at 4-week intervals Semaglutide for weight management (Wegovy): Start at 0.25 mg weekly, increasing through 0.5 mg, 1.0 mg, 1.7 mg to 2.4 mg at approximately 4-week intervals Liraglutide for weight management (Saxenda): Start at 0.6 mg daily, increasing by 0.6 mg increments weekly to a target of 3.0 mg daily This titration schedule is evidence-based and should not be accelerated without medical supervision
